Form 8-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 12, 2012

 

 

PHARMERICA CORPORATION

(Exact Name of Registrant as Specified in Its Charter)

 

 

 

Delaware   001-33380   87-0792558

(State or Other Jurisdiction

of Incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

1901 Campus Place

Louisville, Kentucky 40299

(Address of principal executive offices) (Zip Code)

(502) 627-7000

(Registrant’s telephone number, including area code)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 


Item 5.07 Submission of Matters to a Vote of Security Holders.

The 2012 Annual Meeting of Stockholders of the Company was held on June 12, 2012.

 

1. The Company’s stockholders approved the election of the following eight directors for a term to expire at the Annual Meeting of Stockholders in 2013. The votes for each director were as follows:

 

Name

   For      Withheld Authority      Broker Non-Votes  

Frank E. Collins, Esq.

     24,609,887         169,734         2,437,477   

W. Robert Dahl, Jr.

     24,611,451         168,170         2,437,477   

Marjorie W. Dorr

     24,536,148         243,473         2,437,477   

Thomas P. Gerrity, Ph.D.

     24,527,073         252,548         2,437,477   

Thomas P. Mac Mahon

     24,536,443         243,178         2,437,477   

Geoffrey G. Meyers

     24,609,152         170,469         2,437,477   

Robert A. Oakley, Ph.D.

     24,618,451         161,170         2,437,477   

Gregory S. Weishar

     24,615,655         163,966         2,437,477   

 

2. The Company’s stockholders voted upon the ratification of the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2012. The votes on this proposal were as follows:

 

For

  

Against

  

Abstained

27,180,793

   33,868    2,437

 

3. The Company’s stockholders voted upon and approved, by advisory vote, the compensation of the Company’s named executive officers. The votes on this proposal were as follows:

 

For

  

Against

  

Abstained

  

Broker Non-Votes

23,905,302

   710,951    163,368    2,437,477


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

     PHARMERICA CORPORATION
Date: June 15, 2012    By:    /s/ Thomas A. Caneris
      Thomas A. Caneris
      Senior Vice President, General Counsel, Chief Compliance Officer, and Secretary